DOCSLIB.ORG

Inositol Hexaniacinate: a Safer Alternative to Niacin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inositol Hexaniacinate: a Safer Alternative to Niacin Inositol Hexaniacinate: A Safer Alternative to Niacin Kathleen A. Head, N.D. Abstract Niacin has long been prescribed for the treatment of various cardiovascular con- ditions, particularly the hyperlipidemias. It has been proven effective at lowering VLDL, LDL, total cholesterol and triglyceride levels while raising HDL levels. The side effects of niacin which may occur at the dosages often required for therapeutic efficacy, rang- ing from flushing and pruritus to hepatoxicity and impaired glucose tolerance, often prove troubling for both patient and practitioner. The need for a safer approach to niacin supplementation has resulted in the investigation of niacin esters. One of the most widely studied of these is inositol hexaniacinate (IHN). In numerous trials it has been found to be virtually free of the side effects associated with conventional niacin therapy. Extensive research has found IHN to be effective in the treatment of hyperlipi- demia, Raynaud’s disease and intermittent claudication. A number of other conditions which respond favorably to niacin therapy such as hypertension, diabetes, dysmennorhea and alcoholism bear further investigation. (Alt Med Rev 1996;1(3):176-184.) Importance of Niacin to Human Health: Niacin (B3, nicotinic acid) is vital to cellular metabolism, principally through its role in the coenzymes, nicotine-adenine dinucleotide (NAD) and nicotine-adenine dinucleotide phosphatate (NADP), in oxidation-reduction reactions. Niacin is primarily metabolized in the liver to niacinamide (nicotinamide) and other derivatives. Niacinamide is, in turn, a precursor to NAD and NADP.1 Due to its vasodilatory effects, niacin (but not niacinamide) has, for decades, been prescribed by orthodox and alternative practitioners alike for the treatment of cardiovascular disease, particularly the hyperlipidemias.1-2 In addition, the use of niacin for the treatment of peripheral vascular disorders including Raynaud’s disease and intermittent claudi- cation has been widely studied.3-6 Besides the use of niacin in therapeutic doses, there are certain fractions of the general population that may be deficient in niacin, requiring supplemen- tation to prevent pellagra (the disease of niacin deficiency). These groups include alcoholics7 and the elderly.8 Adverse Effects of Niacin: Although niacin has numerous therapeutic benefits, it may also result in a considerable number of side effects both acute and chronic, subjective and objective. The acute, subjective symptoms include flushing, particularly of the face and neck with pruritis and burning skin, GI complaints and weakness.9 These effects are due to histamine release from the mast cells, starting approximately 20 minutes after ingestion and lasting from one to one and a half hours. Page 176 Alternative Medicine Review ◆ Volume 1, Number 3 ◆ 1996 Copyright©1996 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission Inositol Hexaniacinate FIGURE 1. Side effects are often N rare.1 Coppola and minimized by the ad- Brady12 reported on N dition of aspirin N four cases of niacin- which may create CO induced hepatotoxic- further problems. O ity. All four were tak- Although there may OCO OCO ing sustained-release also be a reduction of niacin. Fulminant symptoms after sev- Esterase liver failure may oc- HO OCO eral days by increas- O cur with the use of ing the dose gradu- COOH high doses of sus- ally and by taking CO tained-release niacin the niacin with N as evidenced by the N meals, many people N case of a 44-year- discontinue its use NIACIN old male who devel- before ever reaching oped liver failure af- optimal therapeutic ter three days on 6 doses. Sustained-release niacin preparations grams daily of timed-release niacin, reported may minimize flushing but result in more gas- by Mullin et al.13 He had previously consumed trointestinal complaints, according to at least up to 6 grams daily of regular crystalline nia- one study.1 Chronic conditions may also re- cin. After 16 months on this regime his liver sult from the use of niacin. These may in- enzymes had remained normal. Gibbons et clude hepatoxicity, hyperuricemia, glucose al14 reported on the prevalence of side-effects intolerance, ocular effects, exacerbation of of both sustained-release and regular niacin peptic ulcer, postural hypotension, particularly in a clinical setting. 110 patients in 133 sepa- in patients taking antihypertensive agents, and rate trials were given nicotinic acid during a skin disorders including acanthosis nigricans.1-2 five year period. The results were that 43% of The ocular effects may include decreased vi- individuals given regular nicotinic acid and sion, cystoid macular edema, periorbital 42% of those receiving the sustained-release edema, loss of eyebrows or eyelashes and su- form were forced to discontinue treatment perficial punctate keratitis. These may occur because of side-effects.14 with the use of niacin in high doses and are 10 reversible if it is discontinued. Niacin com- Inositol Hexaniacinate: petes with uric acid for renal excretion with subsequent elevation of serum uric acid levels. Biochemistry and Metabolism On rare occasions, this may lead to the de- Because of the therapeutic importance velopment of gout or uric acid kidney stones.11 of this vitamin it is imperative that we explore The hepatotoxic effects are perhaps of safer and perhaps more effective forms of ad- the most concern to those administering this ministration. One such form, and probably therapy on a long-term basis. Abnormalities the most studied, is the hexanicotinic acid es- noted on liver function tests may include dose ter of meso-inositol, inositol hexaniacinate related increases in aspartate aminotransferase (IHN), also called inositol hexanicotinate or and alkaline phosphatase. Liver pathology inositol nicotinate. The compound consists of may include cholestasis, hepatocellular disar- six molecules of nicotinic acid and one mol- ray and nodular formation by fibrous tissue. ecule of inositol (See Figure 1).15 It is me- Severe liver toxicity with regular niacin is quite tabolized in the body into its component parts, Alternative Medicine Review ◆ Volume 1, Number 3 ◆ 1996 Page 177 Copyright©1996 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission niacin and inositol (hexahydroxycyclohexane). Raynaud’s disease and intermittent claudica- In the United States it was first described by tion. Promising applications which bear fur- Badgett et al. in 1945.15 It appears that the ther investigation include its use for stasis ulcers, compound is slowly metabolized, not reach- dysmenorrhea, dermatitis herpetiformis, alcohol- ing maximum serum levels for approximately ism, diabetes, cancer prevention and hyperten- 10 hours after ingestion.15 When IHN is ad- sion. These will each be addressed below. ministered orally to humans, the result is a sustained increase in the level of free nicotinic Hyperlipidemia: acid in blood and plasma.16 Pharmacokinetic Numerous epidemiological studies, studies have indicated that these esters are, at both prospective and retrospective, have least in part, absorbed intact and hydrolyzed demonstrated that hyperlipidemia is a major in the body with release of free niacin and risk factor for the development of athero- inositol. The rise in niacin levels was more sclerosis. High levels of very low density than could be explained by observation of the lipoproteins (VLDL), low density lipopro- rate of hydrolysis of these esters in buffered teins (LDL), total cholesterol and triglycer- solutions of various pHs, designed to simu- ides correlate positively with an increased late the gastric and intestinal juices. There- risk for cardiovascular disease (CVD) while fore, it was assumed that another mechanism elevated levels of high density lipoproteins was involved. This was demonstrated by (HDL) convey cardioprotection.2,20 Harthon and Brattsand16 to be an active, en- Niacin, in doses up to 6 grams daily, zymatic hydrolysis in the bloodstream. has long been known to effectively reduce trig- lycerides, total cholesterol, and LDL choles- Safety of Inositol Hexaniacinate terol while at the same time elevating HDL IHN appears to be safe and free of side levels1,2,21,22 Supplemental niacin will also effects at doses up to 4 grams. Welsh and Ede reduce the risk of MI in patients with a previ- studied a group of 153 patients with a variety ous history.23 Niacin appears to effect blood of conditions ranging from Raynaud’s disease lipids by a number of different mechanisms. to psoriasis and reported not a single side ef- It lowers LDL and triglyceride levels by de- fect, with doses ranging from 600 to 1800 mg creasing VLDL synthesis in the liver. This daily. They compared this to patients with the decrease occurs as a chain reaction, beginning same conditions receiving nicotinic acid. Ap- with the activation of the enzyme, phosphodi- proximately 1/3 of them reported one or more esterase and inhibition of adenylate cyclase of the following symptoms: flushing, nausea, activity by nicotinic acid. This in turn inhib- vomiting, giddiness and weakness. Further- its cAMP production in adipocytes.. There is more, the IHN patients tolerated without side a subsequent decrease in release of free fatty effects dosages 3 or 4 times larger than the acids (FFA) from peripheral adipose tissue nicotinic acid group.15 Numerous other in- resulting in a decrease in FFA transport to the vestigators, studying the use of dosages of IHN liver followed by a reduction of VLDL forma- in the range of 4 grams daily, reported not a tion which results in a decrease in the LDL single adverse reaction.3,17-19 cholesterol fraction. The decrease in VLDL and LDL then leads to a decrease in serum trig- Therapeutic Applications of IHN lycerides, phospholipids and cholesterol which IHN has a fairly broad range of thera- generally combine with these lipoproteins.24 peutic applications. The most well researched Niacin also inhibits cholesterol synthe- conditions include the hyperlipidemias, sis from acetate in the liver and appears to Page 178 Alternative Medicine Review ◆ Volume 1, Number 3 ◆ 1996 Copyright©1996 Thorne Research, Inc.
Load more

Recommended publications
  • Inline-Supplementary-Material-1.Pdf
    Appendix 1: STOPP/START criteria version 2 applied to the TRUST dataset Physiological system Criteria Criteria included Number (%) (The relevant () criteria for each participant were applied to the dataset and recorded in of Microsoft Office Excel ® (2013)) criteria included out of total criteria STOPP criteria Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. X 1/3 (33.3) A2. Any drug prescribed beyond the recommended duration, where treatment duration is X well defined. A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent). Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence X 7/13 (53.8) of benefit). B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of profound hypotension, asystole). B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias X (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). B8. Thiazide diuretic with current significant hypokalaemia (i.e.
    [Show full text]
  • Raynaud's Phenomenon and the Possible Use of Foods
    JFS R: Concise Reviews/Hypotheses in Food Science Raynaud’s Phenomenon and the Possible Use of Foods CHRIS I. WRIGHT, CHRISTINE I. KRONER, AND RICHARD DRAIJER R: Concise Reviews in Food Science ABSTRACT: In this article we focus on the possible use of foods to alleviate Raynaud’s phenomenon (RP). RP is evoked, predominately, by cold and results in a potent vascular constriction of the microvascular blood vessels in the hands, thus leading to reduced hand blood flow and the elevation of pain sensation. To alleviate RP by diet, food components need to be able to promote hand skin blood flow, which may be achieved using fish oil, garlic, ginkgo biloba, L-carnitine, or inositol nicotinate, or to increase hand skin temperature, using evening primrose oil, ginkgo biloba, or inositol nicotinate. Although there are a number of studies documenting such improvements with these ingredients, they often are poorly designed. Hence, there is a need for more controlled studies to substantiate their use, but also to test alternative foods or target new ones. Therefore, we also discuss some alternate food options and briefly outline clinical drugs for the treatment of RP, as their mechanisms of action may also be possible targets for food. It is the intention of this article to address the research needs of this field and to provide a better understanding of alternative options for those with RP. Keywords: Raynaud’s, vascular constriction, dietary intervention, nutraceutical, functional foods Introduction Mahoney 1999; Generini and others 2003; Herrick 2003); however, lit- here are a growing number of studies focusing on the con- tle work has been published on the use of foods as a complementary Tceivable health benefits of foods, botanicals, and supplements treatment for RP patients or as a safeguard for those at high or future (Boelsma and others 2001; Green and others 2003).
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Raynaud's Phenomenon and Erythromelalgia
    Temperature-associated vascular disorders: Raynaud’s phenomenon and erythromelalgia. INTRODUCTION We are too much accustomed to attribute to a single cause that which is the product of several, and the majority of our controversies come from that. Baron Justus von Leibig (1803-73) Superficially, Raynaud's phenomenon, a disease associated with cold, and erythromelalgia, a warmth related disorder, could be considered the antithesis of each other. However, both these microcirculatory disorders, first described in the second half of the nineteenth century, have many features in common and, indeed, may share the same etiology, that is microvascular ischemia. The complicated structure that is the microcirculation can produce a variety of responses to a single noxious stimulus with sensations of cold and heat at opposite ends of the spectrum. In this chapter Raynaud's phenomenon and erythromelalgia -are compared and contrasted so that the correct diagnosis of 'these conditions and appropriate remedy can be selected by the clinician. Raynaud's Phenomenon Maurice Raynaud first defined the syndrome which bears his name 133 years ago.1 He described episodic digital ischemia provoked by cold and emotion. It is classically manifest by pallor of the affected part followed by cyanosis and rubor. Vasospasm in the digital vessels leads to the pallor (Fig. 22.1). The subsequent static venous blood leads to the development of cyanosis. The rubor is caused by hyperemia after the return of blood flow. Raynaud's phenomenon (RP) can be a benign condition but, if severe, can cause digital ulceration and gangrene. It is nine times more common in women than in men and has an overall prevalence in the population of approximately 10%, although it may affect as many as 20-30% of women in the younger age groups.2 There is also a familial predisposition which is more marked if the age of onset is less than 30 years.3 Until recently little was known about the true etiology and the extent of the disorder.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 April 2020 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 April 2020 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]